Carlisle
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 3 / 4.6 / nc / (nc-nc) / Male / 3 / 3.0 / nc / (nc-nc)
Female / 0 / 1.3 / nc / (nc-nc) / Female / 3 / 2.2 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.1 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 3 / 2.6 / nc / (nc-nc)
Female / 29 / 19.0 / 152.8 / (102.3-219.5) / Female / 1 / 1.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 2.3 / 216.8 / (69.9-505.9)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 0 / 0.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 3 / 7.3 / nc / (nc-nc)
Female / 4 / 5.2 / nc / (nc-nc) / Female / 1 / 1.9 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 1.4 / nc / (nc-nc) / Male / 0 / 1.4 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 1.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.4 / nc / (nc-nc) / Male / 20 / 21.8 / 91.9 / (56.1-142.0)
Female / 1 / 0.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 2.4 / nc / (nc-nc) / Male / 1 / 1.2 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.9 / nc / (nc-nc) / Male / 1 / 0.6 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 1.6 / nc / (nc-nc) / Male / 1 / 0.7 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc) / Female / 0 / 2.1 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 1.2 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 2 / 4.0 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 4 / 9.2 / nc / (nc-nc) / Male / 51 / 68.7 / 74.2 / (55.3-97.6)
Female / 3 / 7.0 / nc / (nc-nc) / Female / 52 / 56.0 / 92.9 / (69.4-121.8)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

60

Carver
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 14 / 13.8 / 101.8 / (55.6-170.8) / Male / 7 / 7.3 / 95.5 / (38.3-196.8)
Female / 5 / 4.5 / 110.0 / (35.4-256.6) / Female / 5 / 5.7 / 88.1 / (28.4-205.5)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 2.5 / nc / (nc-nc) / Male / 4 / 2.0 / nc / (nc-nc)
Female / 1 / 2.0 / nc / (nc-nc) / Female / 0 / 1.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.4 / nc / (nc-nc) / Male / 6 / 6.9 / 87.6 / (32.0-190.6)
Female / 38 / 45.8 / 83.0 / (58.7-114.0) / Female / 3 / 5.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 4.8 / 145.0 / (58.1-298.7)
Female / 3 / 2.0 / nc / (nc-nc) / Female / 2 / 2.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 19 / 20.3 / 93.6 / (56.3-146.2)
Female / 21 / 17.8 / 117.7 / (72.8-179.9) / Female / 6 / 4.9 / 121.7 / (44.4-264.8)
Esophagus / Pancreas
Male / 6 / 3.4 / 176.6 / (64.5-384.5) / Male / 4 / 3.8 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 7 / 3.8 / 182.1 / (73.0-375.3)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.0 / nc / (nc-nc) / Male / 54 / 50.7 / 106.5 / (80.0-138.9)
Female / 0 / 0.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 10 / 5.5 / 181.6 / (86.9-333.9) / Male / 4 / 3.5 / nc / (nc-nc)
Female / 7 / 3.3 / 209.6 / (84.0-432.0) / Female / 3 / 1.9 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 2.2 / nc / (nc-nc) / Male / 2 / 1.6 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 7 / 4.3 / 164.2 / (65.8-338.4) / Male / 3 / 1.5 / nc / (nc-nc)
Female / 3 / 3.2 / nc / (nc-nc) / Female / 7 / 4.7 / 147.6 / (59.1-304.1)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.7 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 6 / 9.4 / 64.0 / (23.4-139.3)
Lung and Bronchus / All Sites / Types
Male / 28 / 25.2 / 111.1 / (73.8-160.5) / Male / 193 / 176.0 / 109.7 / (94.7-126.3)
Female / 23 / 22.0 / 104.6 / (66.3-156.9) / Female / 158 / 155.7 / 101.5 / (86.3-118.6)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

61

Charlemont
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 1 / 1.4 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 1 / 0.7 / nc / (nc-nc)
Female / 10 / 5.4 / 185.7 / (88.9-341.5) / Female / 0 / 0.6 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 2.1 / nc / (nc-nc)
Female / 2 / 1.9 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 3 / 6.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 1.1 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 3 / 2.7 / nc / (nc-nc) / Male / 12 / 19.7 / 60.9 / (31.5-106.5)
Female / 0 / 2.3 / nc / (nc-nc) / Female / 17 / 17.5 / 97.0 / (56.5-155.4)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

62

Charlton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 4 / 8.8 / nc / (nc-nc) / Male / 2 / 5.8 / nc / (nc-nc)
Female / 3 / 3.0 / nc / (nc-nc) / Female / 3 / 5.0 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 6 / 2.2 / 276.3 / (100.9-601.3) / Male / 1 / 1.4 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 5 / 5.2 / 97.0 / (31.3-226.3)
Female / 40 / 37.0 / 108.2 / (77.3-147.4) / Female / 6 / 4.2 / 142.9 / (52.2-311.0)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 4.0 / 125.3 / (40.4-292.4)
Female / 2 / 2.0 / nc / (nc-nc) / Female / 1 / 1.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 16 / 13.7 / 117.2 / (66.9-190.3)
Female / 15 / 12.3 / 121.7 / (68.1-200.8) / Female / 4 / 3.9 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 2.4 / nc / (nc-nc) / Male / 2 / 2.6 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 6 / 2.6 / 234.6 / (85.7-510.6)
Hodgkin Lymphoma / Prostate
Male / 1 / 1.0 / nc / (nc-nc) / Male / 36 / 35.8 / 100.5 / (70.4-139.2)
Female / 0 / 0.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 4.2 / nc / (nc-nc) / Male / 2 / 2.3 / nc / (nc-nc)
Female / 3 / 2.4 / nc / (nc-nc) / Female / 1 / 1.4 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.6 / nc / (nc-nc) / Male / 3 / 1.8 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 3.2 / nc / (nc-nc) / Male / 1 / 1.4 / nc / (nc-nc)
Female / 2 / 2.5 / nc / (nc-nc) / Female / 1 / 4.9 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.1 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 11 / 7.2 / 152.1 / (75.8-272.2)
Lung and Bronchus / All Sites / Types
Male / 18 / 16.4 / 109.5 / (64.9-173.1) / Male / 120 / 124.9 / 96.1 / (79.6-114.9)
Female / 19 / 14.1 / 135.2 / (81.4-211.2) / Female / 128 / 117.7 / 108.8 / (90.7-129.3)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

63

Chatham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 25 / 16.8 / 148.7 / (96.2-219.5) / Male / 11 / 7.5 / 147.5 / (73.6-264.0)
Female / 10 / 5.9 / 170.0 / (81.4-312.7) / Female / 9 / 5.3 / 170.0 / (77.6-322.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 2.2 / nc / (nc-nc) / Male / 1 / 2.4 / nc / (nc-nc)
Female / 1 / 1.9 / nc / (nc-nc) / Female / 0 / 1.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 2 / 0.5 / nc / (nc-nc) / Male / 5 / 7.3 / 68.9 / (22.2-160.7)
Female / 74 / 46.4 / 159.4 / (125.2-200.2) / Female / 6 / 6.9 / 86.7 / (31.7-188.8)
Cervix Uteri / Oral Cavity & Pharynx
Male / 4 / 4.8 / nc / (nc-nc)
Female / 2 / 1.6 / nc / (nc-nc) / Female / 2 / 2.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 25 / 23.9 / 104.8 / (67.8-154.7)
Female / 22 / 23.5 / 93.5 / (58.6-141.6) / Female / 10 / 5.2 / 191.8 / (91.8-352.8)
Esophagus / Pancreas
Male / 6 / 3.8 / 155.9 / (56.9-339.4) / Male / 5 / 4.5 / 111.3 / (35.9-259.7)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 7 / 5.1 / 137.7 / (55.2-283.7)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.7 / nc / (nc-nc) / Male / 81 / 58.5 / 138.4 / (109.9-172.0)
Female / 2 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 12 / 5.8 / 207.0 / (106.8-361.6) / Male / 1 / 4.1 / nc / (nc-nc)
Female / 2 / 3.7 / nc / (nc-nc) / Female / 1 / 2.6 / nc / (nc-nc)
Larynx / Testis
Male / 5 / 2.4 / 206.4 / (66.5-481.8) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 4.5 / nc / (nc-nc) / Male / 1 / 1.1 / nc / (nc-nc)
Female / 4 / 3.7 / nc / (nc-nc) / Female / 3 / 3.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.8 / nc / (nc-nc)
Female / 0 / 1.1 / nc / (nc-nc) / Female / 12 / 9.9 / 121.3 / (62.6-211.9)
Lung and Bronchus / All Sites / Types
Male / 19 / 30.0 / 63.3 / (38.1-98.9) / Male / 224 / 198.7 / 112.7 / (98.4-128.5)
Female / 23 / 26.5 / 86.9 / (55.0-130.3) / Female / 209 / 173.8 / 120.3 / (104.5-137.7)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

64

Chelmsford
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 29 / 34.9 / 83.1 / (55.6-119.4) / Male / 18 / 20.5 / 87.7 / (52.0-138.6)
Female / 15 / 13.7 / 109.3 / (61.1-180.3) / Female / 12 / 17.7 / 67.9 / (35.1-118.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 7.1 / nc / (nc-nc) / Male / 4 / 5.4 / nc / (nc-nc)
Female / 2 / 6.1 / nc / (nc-nc) / Female / 1 / 4.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 1.1 / nc / (nc-nc) / Male / 23 / 18.5 / 124.4 / (78.8-186.7)
Female / 157 / 144.5 / 108.7 / (92.3-127.1) / Female / 20 / 17.8 / 112.7 / (68.8-174.0)
Cervix Uteri / Oral Cavity & Pharynx
Male / 10 / 14.2 / 70.2 / (33.6-129.1)
Female / 5 / 6.5 / 77.5 / (25.0-180.8) / Female / 5 / 6.9 / 72.3 / (23.3-168.8)
Colon / Rectum / Ovary
Male / 58 / 53.1 / 109.2 / (83.0-141.2)
Female / 57 / 53.9 / 105.8 / (80.2-137.1) / Female / 15 / 15.4 / 97.3 / (54.4-160.5)
Esophagus / Pancreas
Male / 11 / 9.3 / 118.4 / (59.0-211.8) / Male / 8 / 10.1 / 79.1 / (34.1-155.9)
Female / 3 / 2.7 / nc / (nc-nc) / Female / 6 / 11.5 / 52.1 / (19.0-113.3)
Hodgkin Lymphoma / Prostate
Male / 1 / 2.8 / nc / (nc-nc) / Male / 157 / 146.0 / 107.6 / (91.4-125.8)
Female / 4 / 2.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 20 / 15.7 / 127.5 / (77.8-196.9) / Male / 5 / 8.9 / 56.1 / (18.1-130.8)
Female / 10 / 10.1 / 98.6 / (47.2-181.4) / Female / 4 / 5.7 / nc / (nc-nc)
Larynx / Testis
Male / 5 / 6.1 / 81.4 / (26.2-190.1) / Male / 6 / 5.0 / 120.0 / (43.8-261.2)
Female / 1 / 1.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 13 / 11.4 / 114.5 / (60.9-195.7) / Male / 9 / 4.6 / 197.4 / (90.1-374.7)
Female / 11 / 9.7 / 113.2 / (56.4-202.5) / Female / 14 / 15.0 / 93.5 / (51.1-156.8)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 11 / 7.6 / 144.6 / (72.1-258.7)
Female / 2 / 2.8 / nc / (nc-nc) / Female / 36 / 30.3 / 118.7 / (83.1-164.3)
Lung and Bronchus / All Sites / Types
Male / 67 / 66.8 / 100.3 / (77.7-127.4) / Male / 497 / 481.9 / 103.1 / (94.3-112.6)
Female / 61 / 65.8 / 92.7 / (70.9-119.1) / Female / 468 / 480.2 / 97.5 / (88.8-106.7)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

65

Chelsea
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 30 / 30.5 / 98.3 / (66.3-140.3) / Male / 6 / 17.7 / 33.9 / (12.4-73.7)
Female / 8 / 10.6 / 75.8 / (32.6-149.4) / Female / 11 / 14.4 / 76.2 / (38.0-136.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 6 / 6.5 / 92.7 / (33.8-201.7) / Male / 9 / 4.6 / 195.1 / (89.0-370.4)
Female / 8 / 5.1 / 156.6 / (67.4-308.6) / Female / 1 / 3.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.9 / nc / (nc-nc) / Male / 17 / 16.3 / 104.5 / (60.8-167.3)
Female / 87 / 104.1 / 83.5 / (66.9-103.1) / Female / 17 / 13.9 / 122.2 / (71.2-195.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 20 / 11.1 / 180.9 / (110.4-279.3)
Female / 13 / 5.3 / 246.3 / (131.0-421.2) / Female / 2 / 5.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 51 / 45.4 / 112.3 / (83.6-147.6)
Female / 45 / 42.3 / 106.3 / (77.5-142.2) / Female / 10 / 11.4 / 87.5 / (41.9-160.9)
Esophagus / Pancreas
Male / 16 / 7.6 / 210.7 / (120.3-342.2) / Male / 9 / 8.5 / 105.6 / (48.2-200.5)
Female / 1 / 2.0 / nc / (nc-nc) / Female / 6 / 9.0 / 66.8 / (24.4-145.5)
Hodgkin Lymphoma / Prostate
Male / 4 / 3.2 / nc / (nc-nc) / Male / 86 / 114.0 / 75.4 / (60.3-93.1)
Female / 0 / 2.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 20 / 12.7 / 157.9 / (96.4-243.8) / Male / 10 / 7.9 / 127.1 / (60.9-233.8)
Female / 7 / 7.6 / 92.2 / (36.9-190.0) / Female / 5 / 4.7 / 107.2 / (34.5-250.2)
Larynx / Testis
Male / 13 / 4.9 / 265.6 / (141.3-454.3) / Male / 1 / 6.1 / nc / (nc-nc)
Female / 5 / 1.3 / 391.2 / (126.1-912.9)
Leukemia / Thyroid
Male / 8 / 10.4 / 76.6 / (33.0-151.0) / Male / 4 / 4.0 / nc / (nc-nc)
Female / 7 / 8.2 / 85.3 / (34.2-175.7) / Female / 12 / 13.0 / 92.5 / (47.8-161.7)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 12 / 6.1 / 198.0 / (102.2-346.0)
Female / 4 / 2.2 / nc / (nc-nc) / Female / 21 / 21.1 / 99.6 / (61.6-152.2)
Lung and Bronchus / All Sites / Types
Male / 62 / 55.9 / 110.8 / (85.0-142.1) / Male / 416 / 404.0 / 103.0 / (93.3-113.4)
Female / 51 / 48.5 / 105.2 / (78.3-138.3) / Female / 354 / 364.3 / 97.2 / (87.3-107.8)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

66

Cheshire
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 5 / 4.4 / 113.9 / (36.7-265.8) / Male / 1 / 2.4 / nc / (nc-nc)
Female / 1 / 1.3 / nc / (nc-nc) / Female / 4 / 1.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 0.8 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 2 / 0.6 / nc / (nc-nc) / Female / 2 / 0.4 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 3 / 2.2 / nc / (nc-nc)
Female / 18 / 13.9 / 129.7 / (76.8-205.0) / Female / 2 / 1.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 1.7 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 8 / 6.6 / 120.8 / (52.0-238.0)
Female / 6 / 5.0 / 121.1 / (44.2-263.6) / Female / 0 / 1.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 3 / 1.1 / nc / (nc-nc) / Male / 0 / 1.3 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 4 / 1.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.3 / nc / (nc-nc) / Male / 15 / 17.9 / 84.0 / (47.0-138.6)
Female / 0 / 0.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 1.9 / nc / (nc-nc) / Male / 0 / 1.1 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 4 / 1.4 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 1 / 1.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.9 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 2.9 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 12 / 8.3 / 144.7 / (74.7-252.8) / Male / 61 / 58.9 / 103.5 / (79.2-133.0)
Female / 12 / 6.2 / 192.5 / (99.3-336.2) / Female / 56 / 45.4 / 123.2 / (93.1-160.0)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

67

Chester
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 1 / 1.4 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 5 / 5.0 / 101.0 / (32.5-235.6) / Female / 1 / 0.6 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.6 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 2 / 2.1 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 2 / 0.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.1 / nc / (nc-nc) / Male / 3 / 5.7 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 2 / 1.0 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 3 / 2.7 / nc / (nc-nc) / Male / 13 / 19.4 / 67.1 / (35.7-114.8)
Female / 1 / 2.1 / nc / (nc-nc) / Female / 18 / 15.9 / 112.9 / (66.9-178.4)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

68

Chesterfield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 1 / 1.2 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 2 / 0.6 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 4 / 4.6 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.5 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.9 / nc / (nc-nc)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 1 / 0.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 3 / 5.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 1.0 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 2.4 / nc / (nc-nc) / Male / 9 / 17.3 / 51.9 / (23.7-98.6)
Female / 3 / 1.8 / nc / (nc-nc) / Female / 13 / 14.3 / 91.0 / (48.4-155.5)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

69

Chicopee
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 68 / 68.8 / 98.8 / (76.7-125.3) / Male / 28 / 36.1 / 77.5 / (51.5-112.0)
Female / 33 / 26.8 / 123.0 / (84.6-172.7) / Female / 26 / 30.4 / 85.6 / (55.9-125.4)
Brain and Other Nervous System / Multiple Myeloma
Male / 12 / 12.1 / 99.0 / (51.1-172.9) / Male / 10 / 10.2 / 97.9 / (46.8-180.0)
Female / 9 / 10.7 / 84.4 / (38.5-160.2) / Female / 12 / 8.6 / 140.2 / (72.3-244.9)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 2.0 / nc / (nc-nc) / Male / 26 / 33.9 / 76.8 / (50.1-112.5)
Female / 246 / 247.1 / 99.6 / (87.5-112.8) / Female / 26 / 33.7 / 77.1 / (50.3-112.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 25 / 23.9 / 104.7 / (67.8-154.6)
Female / 7 / 10.4 / 67.6 / (27.1-139.3) / Female / 11 / 12.5 / 88.3 / (44.0-158.1)
Colon / Rectum / Ovary
Male / 89 / 101.4 / 87.8 / (70.5-108.0)
Female / 111 / 106.1 / 104.6 / (86.0-125.9) / Female / 27 / 27.1 / 99.6 / (65.6-145.0)
Esophagus / Pancreas
Male / 20 / 17.0 / 117.8 / (71.9-181.9) / Male / 9 / 19.1 / 47.0 / (21.4-89.2)
Female / 4 / 5.2 / nc / (nc-nc) / Female / 18 / 22.9 / 78.7 / (46.6-124.4)
Hodgkin Lymphoma / Prostate
Male / 2 / 4.9 / nc / (nc-nc) / Male / 255 / 257.9 / 98.9 / (87.1-111.8)
Female / 4 / 4.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 22 / 27.4 / 80.2 / (50.3-121.5) / Male / 22 / 17.3 / 126.8 / (79.5-192.1)
Female / 16 / 18.7 / 85.7 / (48.9-139.1) / Female / 13 / 11.4 / 114.0 / (60.6-194.9)
Larynx / Testis
Male / 8 / 10.9 / 73.4 / (31.6-144.6) / Male / 7 / 8.0 / 87.6 / (35.1-180.5)
Female / 3 / 3.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 22 / 21.0 / 104.7 / (65.6-158.6) / Male / 1 / 7.2 / nc / (nc-nc)
Female / 13 / 18.3 / 70.9 / (37.7-121.3) / Female / 17 / 23.7 / 71.8 / (41.8-115.0)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 14 / 13.2 / 105.9 / (57.9-177.8)
Female / 7 / 5.3 / 132.1 / (52.9-272.1) / Female / 67 / 51.5 / 130.2 / (100.9-165.4)
Lung and Bronchus / All Sites / Types
Male / 128 / 127.1 / 100.7 / (84.0-119.8) / Male / 838 / 882.3 / 95.0 / (88.7-101.6)
Female / 110 / 126.2 / 87.2 / (71.6-105.0) / Female / 852 / 872.4 / 97.7 / (91.2-104.4)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

70

Chilmark
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 2 / 1.5 / nc / (nc-nc) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 1 / 0.5 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 3 / 4.5 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.5 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 2.2 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 8 / 5.8 / 137.6 / (59.3-271.2)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 0.6 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 0.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 2.7 / nc / (nc-nc) / Male / 17 / 19.2 / 88.7 / (51.7-142.1)
Female / 4 / 2.1 / nc / (nc-nc) / Female / 10 / 15.1 / 66.1 / (31.6-121.6)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

71

Clarksburg
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 3 / 2.2 / nc / (nc-nc) / Male / 0 / 1.2 / nc / (nc-nc)
Female / 2 / 0.7 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 1 / 1.1 / nc / (nc-nc)
Female / 4 / 7.6 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 3.3 / nc / (nc-nc)
Female / 2 / 2.9 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 0.6 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.2 / nc / (nc-nc) / Male / 6 / 9.4 / 64.1 / (23.4-139.6)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 0.9 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 0.4 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 0.7 / nc / (nc-nc) / Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 2 / 1.6 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 9 / 4.2 / 212.5 / (96.9-403.3) / Male / 28 / 29.8 / 94.0 / (62.4-135.8)
Female / 7 / 3.6 / 193.7 / (77.6-399.2) / Female / 25 / 25.5 / 98.2 / (63.6-145.0)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

72

Clinton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 13 / 14.4 / 90.1 / (47.9-154.0) / Male / 5 / 8.1 / 61.7 / (19.9-143.9)
Female / 5 / 6.0 / 83.3 / (26.8-194.4) / Female / 7 / 7.2 / 97.3 / (39.0-200.5)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 2.8 / nc / (nc-nc) / Male / 2 / 2.2 / nc / (nc-nc)
Female / 0 / 2.5 / nc / (nc-nc) / Female / 3 / 1.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 5 / 7.5 / 67.0 / (21.6-156.4)
Female / 39 / 56.6 / 68.9 / (49.0-94.1) / Female / 6 / 7.6 / 78.5 / (28.7-170.8)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 5.3 / 131.8 / (52.8-271.7)
Female / 6 / 2.5 / 237.6 / (86.8-517.3) / Female / 2 / 2.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 24 / 21.5 / 111.6 / (71.5-166.1)
Female / 22 / 24.0 / 91.5 / (57.3-138.5) / Female / 10 / 6.2 / 161.4 / (77.3-296.9)
Esophagus / Pancreas
Male / 5 / 3.6 / 137.6 / (44.3-321.1) / Male / 2 / 4.1 / nc / (nc-nc)
Female / 2 / 1.2 / nc / (nc-nc) / Female / 3 / 5.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 2 / 1.2 / nc / (nc-nc) / Male / 41 / 55.1 / 74.4 / (53.4-100.9)
Female / 0 / 1.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 3 / 6.0 / nc / (nc-nc) / Male / 3 / 3.7 / nc / (nc-nc)
Female / 6 / 4.2 / 143.0 / (52.2-311.3) / Female / 2 / 2.6 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 2.3 / nc / (nc-nc) / Male / 0 / 2.2 / nc / (nc-nc)
Female / 1 / 0.7 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 4.6 / nc / (nc-nc) / Male / 1 / 1.7 / nc / (nc-nc)
Female / 4 / 4.2 / nc / (nc-nc) / Female / 4 / 5.9 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 2.9 / 172.2 / (55.5-401.9)
Female / 0 / 1.2 / nc / (nc-nc) / Female / 5 / 11.6 / 43.1 / (13.9-100.6)
Lung and Bronchus / All Sites / Types
Male / 31 / 26.8 / 115.6 / (78.6-164.1) / Male / 172 / 190.1 / 90.5 / (77.5-105.0)
Female / 18 / 27.8 / 64.8 / (38.4-102.3) / Female / 158 / 198.7 / 79.5 / (67.6-92.9)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

73

Cohasset
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CI
Bladder, Urinary / Melanoma of Skin
Male / 14 / 8.7 / 160.3 / (87.6-269.0) / Male / 10 / 4.8 / 206.2 / (98.7-379.3)
Female / 3 / 3.2 / nc / (nc-nc) / Female / 14 / 3.9 / 357.3 / (195.2-599.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.7 / nc / (nc-nc) / Male / 2 / 1.3 / nc / (nc-nc)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 6 / 4.4 / 135.2 / (49.4-294.3)
Female / 32 / 32.9 / 97.4 / (66.6-137.5) / Female / 2 / 4.1 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 4 / 3.4 / nc / (nc-nc)
Female / 2 / 1.4 / nc / (nc-nc) / Female / 1 / 1.6 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 16 / 13.2 / 121.6 / (69.5-197.5)
Female / 15 / 12.6 / 119.0 / (66.6-196.3) / Female / 6 / 3.5 / 170.5 / (62.3-371.2)
Esophagus / Pancreas
Male / 1 / 2.3 / nc / (nc-nc) / Male / 3 / 2.5 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 1 / 2.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.6 / nc / (nc-nc) / Male / 35 / 35.2 / 99.4 / (69.2-138.2)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 3.8 / 159.6 / (58.3-347.5) / Male / 1 / 2.2 / nc / (nc-nc)
Female / 1 / 2.4 / nc / (nc-nc) / Female / 0 / 1.3 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.5 / nc / (nc-nc) / Male / 0 / 0.9 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 4 / 2.7 / nc / (nc-nc) / Male / 2 / 1.0 / nc / (nc-nc)
Female / 0 / 2.2 / nc / (nc-nc) / Female / 5 / 3.2 / 156.5 / (50.4-365.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.8 / nc / (nc-nc)
Female / 3 / 0.6 / nc / (nc-nc) / Female / 7 / 6.8 / 102.2 / (40.9-210.6)
Lung and Bronchus / All Sites / Types
Male / 14 / 16.5 / 85.1 / (46.5-142.8) / Male / 130 / 116.9 / 111.3 / (92.9-132.1)
Female / 10 / 15.4 / 65.1 / (31.2-119.8) / Female / 111 / 110.1 / 100.8 / (82.9-121.4)
  • Obs = observed case count; Exp = expected case count;
  • SIR = standardized incidence ratio ( (Obs / Exp) X 100);
  • 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
  • Shading indicates the statistical significance of the SIR at 95% level of probability;
  • nc = The SIR and 95% CI were not calculated when Obs < 5;

74